Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab in Newly Diagnosed Type 1 Diabetes
NCT06111586Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of frexalimab in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Sanofi. Primary endpoint: Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration AUC at 52 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
frexalimab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06111586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111586.